{"id":85329,"date":"2026-06-04T00:03:00","date_gmt":"2026-06-04T00:03:00","guid":{"rendered":"https:\/\/ciaoup.it\/?p=85329"},"modified":"2026-06-04T00:03:00","modified_gmt":"2026-06-04T00:03:00","slug":"era-congress-semaglutide-linked-to-better-quality-of-life-in-diabetes-and-kidney-disease-flow-trial-shows","status":"publish","type":"post","link":"https:\/\/ciaoup.it\/?p=85329","title":{"rendered":"ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows"},"content":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE<\/p>\n

GLASGOW, Scotland, June 4, 2026 \/PRNewswire\/ — New\u00a0findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. \u00a0<\/p>\n

The trial previously demonstrated that semaglutide reduced the risk of major kidney disease events by 24% and all-cause mortality by 20% compared with placebo over a median treatment duration of 3.4 years. This new analysis provides complementary patient-centred evidence, showing that the benefits of semaglutide may extend beyond traditional clinical outcomes to how patients feel and function in everyday life.\u00a0<\/p>\n

For people living with both T2D and CKD, symptoms, treatment burden and reduced physical functioning can substantially affect day-to-day well-being, making quality of life an increasingly important treatment goal.\u00a0<\/p>\n

Among 3,533 randomised participants in the FLOW trial, 1,767 received semaglutide and 1,766 received placebo. Health-related quality of life was assessed using the EQ-5D-5L questionnaire, a patient-reported measure of health status and well-being covering mobility, self-care, usual activities, pain\/discomfort, anxiety\/depression, and overall health perception.\u00a0<\/p>\n

After two years of treatment, health utility scores \u2013 which range from 0 (death) to 1 (perfect health) \u2013 remained stable in the semaglutide group but declined in those receiving placebo. The estimated treatment difference of +0.021 (p=0.0001) corresponded to approximately eight additional days per year spent in full health.\u00a0<\/p>\n

Self-rated general health scores also improved with semaglutide but worsened with placebo, with a significant treatment difference of +2.15 (p<0.0001), again becoming worse over time with placebo while stable on semaglutide.\u00a0<\/p>\n

Four of the five areas assessed by the questionnaire (mobility, self-care, usual activities, and pain\/discomfort) improved significantly with semaglutide compared with placebo. No significant difference was observed in anxiety\/depression. Benefits were broadly consistent across patient subgroups.\u00a0<\/p>\n

“We were surprised by the extent of the quality-of-life benefits seen with semaglutide, because they were not only clinically meaningful but consistently experienced across multiple aspects of daily life, including physical functioning and overall well-being,” said Professor Johannes Mann, study lead author.\u00a0<\/p>\n

“We were uncertain about quality-of-life outcomes because gastrointestinal side effects are common with GLP-1 receptor agonists,” Prof. Mann furthered. “Our findings confirm that the benefits of semaglutide in chronic kidney disease extend beyond traditional clinical endpoints to subjective outcomes that matter directly to patients.”\u00a0<\/p>\n

View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/era-congress-semaglutide-linked-to-better-quality-of-life-in-diabetes-and-kidney-disease-flow-trial-shows-302790075.html
\n\u00a0<\/p>\n

Copyright 2026 PR Newswire. All Rights Reserved.\u00a0<\/p>\n

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi<\/p>\n

—<\/p>\n

immediapress\/pr-newswire<\/p><\/p>\n

\n\t\t<\/a>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE GLASGOW, Scotland, June 4, 2026 \/PRNewswire\/ — New\u00a0findings from the…<\/p>\n","protected":false},"author":3,"featured_media":85330,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[23],"class_list":["post-85329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicati","tag-immediapress"],"_links":{"self":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/85329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=85329"}],"version-history":[{"count":1,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/85329\/revisions"}],"predecessor-version":[{"id":85340,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/85329\/revisions\/85340"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/media\/85330"}],"wp:attachment":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=85329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=85329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=85329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}